Mitchell Fuerst Featured Speaker at Upcoming Stem Cell and Age Management Medicine Conference and Meeting

Nov 09, 2010   

Fuerst Ittlemans Managing Partner, Mitchell S. Fuerst, Esq., is a featured speaker and participant at a series of upcoming meetings and conferences focused on stem cell medicine and age management medicine.

Fuerst will be speaking on the "Practice of Medicine “ Physicians, Stem Cells and the Current Regulatory Environment" at the annual conference of the Age Management Medicine Group (AMMG) in Las Vegas, NV, on November 11, 2010.  The conference, entitled "Clinical Applications for Age Management Medicine," brings together leading healthcare professionals, physicians, researchers and others to provide education and information on the preservation of optimum human function and quality of life making every effort to modulate the process of aging prior to the onset of degenerative aging.

In addition to traditional medicine, alternative medicine therapies, and general health and nutritional régimes, age management medicine focuses on regenerative and stem cell therapies.  The leading professional, non-profit organization devoted to researching, promoting and safeguarding stem cell therapies and its related research, the International Cellular Medicine Society (ICMS), will be holding its annual membership meeting and congress concurrent with the AMMG conference.

The 2nd Annual International Congress on Regenerative and Cell Based Medicine, sponsored by ICMS and Fuerst Ittleman, will bring together medical practitioners from dozens of countries to discuss the latest developments in cell-based medical therapies and will feature presentations on the therapeutic use of platelet rich plasma, adipose tissue, bone marrow, and peripheral blood.  As one of the foremost authorities on the governmental regulation of stem cell therapies and medical professionals who practice in the field, Mitchell Fuerst is featured at the Congress as a faculty member.

In addition to its Congress, ICMS will also be conducting its annual general membership meeting, at which Mr. Fuerst will serve as a panel member discussing "Severe Adverse Events and Cell Based Medicine."  The panel is expected to discuss FDA regulation over stem cell therapies and the various ways in which the FDA could attempt investigation and enforcement actions regarding the practice of that particular form of medicine.

For more information on Fuerst Ittlemans experience in the legal aspects of stem cell therapies, age management medicine, food and drug law in general, and FDA regulatory and enforcement actions, please visit our Food, Drug and Cosmetic Law practice page.